You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 27 No. 1, July 1972 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Phenylethylmalonamide (PEMA)

An Important Metabolite of Primidone

Irwin P. Baumel, PhD; Brian B. Gallagher, MD, PhD; Richard H. Mattson, MD

Arch Neurol. 1972;27(1):34-41.


Abstract

A gas chromatographic method for the determination of primidone and its metabolites, phenylethylmalonamide (PEMA) and phenobarbital in serum, has been described. After a single oral dose of primidone in man, PEMA appeared readily in serum, whereas phenobarbital was undetectable. The biological half-life of primidone after a single dose in man was 3.3 to 7.0 hours with an estimated half-life of 30 hours for PEMA. In epileptic subjects receiving primidone chronically, both PEMA and phenobarbital accumulated in serum. Binding of primidone or PEMA to serum protein was negligible, while phenobarbital was 60% bound. In high doses PEMA showed anticonvulsant activity in rats using the convulsant hexafluorodiethyl ether. In low doses PEMA potentiated the anticonvulsant activity of phenobarbital in rats. In addition, hexobarbital sleeping time in rats was prolonged after injection of PEMA.



Author Affiliations

New Haven, Conn

From the Department of Neurology, Yale University School of Medicine, New Haven, Conn.


Footnotes

Accepted for publication Feb 19, 1972.

Read before the Symposium on Pharmacology of Antiepileptic Drugs, Scottsdale, Ariz, Sept 9, 1971.

Reprint requests to Department of Neurology, Yale University School of Medicine, 333 Cedar St, New Haven, Conn 06510 (Dr. Baumel).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Physiologically Based Pharmacokinetics Model of Primidone and Its Metabolites Phenobarbital and Phenylethylmalonamide in Humans, Rats, and Mice
El-Masri and Portier
Drug Metab. Dispos. 1998;26:585-594.
ABSTRACT | FULL TEXT  

Acetazolamide-Induced Interference With Primidone Absorption: Case Reports and Metabolic Studies
Syversen et al.
Arch Neurol 1977;34:80-84.
ABSTRACT  

Acute Primidone Intoxication
Brillman et al.
Arch Neurol 1974;30:255-258.
ABSTRACT  

Methsuximide Overdose: Delayed Onset of Profound Coma
Karch
JAMA 1973;223:1463-1465.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1972 American Medical Association. All Rights Reserved.